FAS and metabolic dysfunction-associated steatotic liver disease: The results showed SFA reversed the decline of phosphorylated AMPK, followed by the downregulation of SREBP1c and FAS, thus preventing hepatic TG synthesis both in the cell and mice model of NAFLD.